New study shows advance in CAR T-cell therapy eliminates severe side effects

          Source: Xinhua| 2019-04-23 18:39:02|Editor: xuxin
          Video PlayerClose

          LOS ANGELES, April 23 (Xinhua) -- An advance in the breakthrough cancer treatment known as CAR T-cell therapy appears to eliminate its severe side effects, making the treatment safer and potentially available in outpatient settings, according to a new study of the University of Southern California (USC).

          "This is a major improvement. We've made a new CAR molecule that is just as efficient at killing cancer cells, but it works more slowly and with less toxicity," said Si-Yi Chen of the USC Norris Comprehensive Cancer Center, and senior author of the study appearing online Monday in Nature Medicine.

          This improved version of CAR T therapy produced no serious side effects in 25 patients who had lymphoma that recurred after previous treatments. Although the study was designed to look at safety, not effectiveness, six out of 11 participants receiving a commonly used dose went into complete remission.

          CAR T therapy involves harvesting immune cells called T cells from a patient's blood and then modifying them in the lab to produce special structures called chimeric antigen receptors (CAR) on their surface.

          The altered T cells are reinfused into the patient, where the cells' new receptors enable them to recognize and latch onto cancer cells, killing them.

          Approved by the U.S. Food and Drug Administration less than two years ago, CAR T is a literal lifesaver for some people with leukemia and lymphoma, bringing lasting remissions to those on the brink of death.

          The downside is that the treatment often causes severe side effects -- some of them life-threatening -- which must be managed by experienced specialists.

          In this revised version, researchers tweaked the sequence and shape of the CAR molecules. As a result, the CAR T cells kill cancer cells but produce fewer cytokines and proliferate more slowly, giving the patient's body more time to clear cytokines in the blood.

          "The improved CAR T cells proliferated and differentiated into memory cells in the patients, thus producing a potent and long-lasting anti-tumor effect without causing toxicities," Chen said.

          The research team's next step is to perform a multi-center phase II to test safety and effectiveness in a larger group of patients.

          TOP STORIES
          EDITOR’S CHOICE
          MOST VIEWED
          EXPLORE XINHUANET
          010020070750000000000000011100001380019091
          无码人妻一区二区三区四区av_亚洲精品911在线永久观看_精品一区二区国产在线观看_日韩不卡一区二区视频在线

                  伊人久久精品亚洲午夜 | 色五月婷婷久久综合 | 一区与二区精品在线 | 亚洲欧美久久综合网站点击 | 婷婷精品视频在线观看的 | 亚洲最大的中文视频网站 |